The International Federation of Gynaecology and Obstetrics (FIGO) updated its staging system for endometrial cancer in June 2023. The new system includes nonanatomic histological parameters and molecular classification, which are not traditionally part of staging systems. In August 2023, a survey was conducted among pathologists and clinicians to determine their views on adopting the FIGO 2023 system in the UK. The results showed no consensus on whether to incorporate the new parameters into staging, and only 34% of respondents favored adopting FIGO 2023. Access to timely molecular testing was identified as a factor that correlated with support for adoption. The British Association of Gynaecological Pathologists (BAGP) and British Gynaecological Cancer Society (BGCS) currently do not recommend adopting FIGO 2023 in the UK due to controversies and limited access to molecular classification. [Extracted from the article]